ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2025
Efficacy and Safety of Luseogliflozin in Patients with Type 2 Diabetes Mellitus: An Umbrella Review of Systematic Reviews.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with rising global prevalence, requiring effective management to prevent complications. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, including luseogliflozin, are a novel class of drugs that provide benefits beyond glycemic control. This umbrella review synthesized evidence from multiple systematic reviews and meta-analyses to evaluate the efficacy and safety of luseogliflozin in T2DM patients. Following Joanna Briggs Institute (JBI) guidelines and PRISMA standards, eligible studies included systematic reviews and meta-analyses of randomized controlled trials (RCTs) and observational studies involving adult T2DM patients treated with luseogliflozin. A comprehensive literature search was performed in PubMed, EMBASE, and Web of Science up to June 10, 2024. Data extraction and quality assessment were independently conducted by two reviewers, and statistical analyses were performed using R software version 4.3. Fourteen systematic reviews were included, showing that luseogliflozin significantly reduced HbA1c levels (pooled mean difference -1.784, 95% CI: -3.99 to -0.431), fasting plasma glucose (FPG) levels (-3.165, 95% CI: -4.046 to -2.284), and postprandial glucose (PPG) levels (-37.148, 95% CI: -65.361 to -8.935) compared with placebo. Additional benefits included significant reductions in body weight (-1.322 kg, 95% CI: -1.58 to -1.056), triglycerides (-13.891, 95% CI: -26.539 to -1.243), uric acid (-0.350, 95% CI: -0.524 to -0.176), and alanine aminotransferase (ALT) levels (-7.345, 95% CI: -5.845 to -1.463). No significant increase in hypoglycemia risk was observed (pooled risk ratio 1.305, 95% CI: 0.692 to 2.459). These findings suggest that luseogliflozin is an effective and safe treatment for T2DM, offering substantial benefits in glycemic control, weight management, blood pressure lowering, and metabolic parameters, with a favorable safety profile regarding hypoglycemia. Further long-term studies are warranted to establish its definitive role in clinical practice and support broader regulatory approvals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.